TerminatedPhase 3NCT03398837
Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
Studying Diffuse cutaneous systemic sclerosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Corbus Pharmaceuticals Inc.
- Principal Investigator
- Robert Spiera, MDProfessor of Clinical Medicine, Weill Cornell Medical College
- Intervention
- Lenabasum 5 mg(drug)
- Enrollment
- 365 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2020
Study locations (30)
- University of California San Diego, La Jolla, California, United States
- Pacific Arthritis Care Center, Los Angeles, California, United States
- UCLA, Los Angeles, California, United States
- Stanford University, Palo Alto, California, United States
- University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
- Georgetown University Medical Center, Washington D.C., District of Columbia, United States
- Northwestern University, Chicago, Illinois, United States
- Tulane University Medical Center, New Orleans, Louisiana, United States
- John Hopkins University, Scleroderma Center, Baltimore, Maryland, United States
- Massachusetts General Hospital, Division of Rheumatology, Boston, Massachusetts, United States
- Boston University Medical Center (BUMC) - General Clinical Research Unit (GCRU), Boston, Massachusetts, United States
- Michigan Medicine, Ann Arbor, Michigan, United States
- University of Minnesota Health Clinical Research Unit, Minneapolis, Minnesota, United States
- Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
- Rutgers Clinical Research Center, Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03398837 on ClinicalTrials.govOther trials for Diffuse cutaneous systemic sclerosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07473154Controlling Hyperactive Immunity With Long-lived LymphocytesQuell Therapeutics Limited
- RECRUITINGPHASE1, PHASE2NCT06947473Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.Beijing GoBroad Hospital
- RECRUITINGPHASE2NCT05029336Autologous Stem Cell Transplant (ASCT) for Autoimmune DiseasesStephan Grupp MD PhD
- RECRUITINGPHASE2NCT07047690A Study of Nemolizumab for the Treatment of Adults With Systemic SclerosisGalderma R&D
- RECRUITINGPHASE2NCT07287670EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)Mediar Therapeutics
- RECRUITINGNCT07256418Transcriptomic Study of Cutaneous Fibroblasts in SclerodermaCentre Hospitalier Universitaire Dijon
- RECRUITINGPHASE1NCT07295847A Study of AZD0120 in Autoimmune DiseasesAstraZeneca
- RECRUITINGNANCT07292961Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed With SclerodermaHacettepe University